Search Results

The SanBio Group today announced it is one of the founding member organizations of the National TBI Registry Coalition (NTRC) in the United States.

SanBio Announces Publication of STEMTRA Phase 2 Interim Analysis for SB623 in Neurology Publication Affirms SanBio’s Approach to Treating Chronic Traumatic Brain Injury Patients

The SanBio Group hereby announces the completion of an application filing with Japan’s Ministry of Health, Labour, and Welfare for manufacture and marketing approval as a regenerative medicine product for the investigational product SB623, as a treatment for chronic motor deficit from traumatic brain injury.

The SanBio Group, hereby announce that data comparing outcome measures for persons with traumatic brain injury living with chronic motor deficits was published in Expert Review of Neurotherapeutics.

Proposed Acquisition Valued at Approximately $15 Million Would Add an Established 50-State Telehealth Business, with over 90,000 clients, Focused on Peptides such as GLP-1 Weight Management, Hormone Health, Longevity and Sexual Wellness Key Highlights: • Target generated approximately $12.7 million in revenue for the trailing twelve months ended August 2026 (unaudited, as provided by Target management) and is cash-flow positive • Proposed purchase price of approximately $15 million, payable in cash and KALA stock; the cash portion is expected to be funded from existing balance sheet resources • Founded in 2023; LegitScript-certified, NABP-accredited platform serving clients in all 50 states; more than 90,000 clients served since inception • 45-day due diligence period expected to conclude in November 2026; definitive agreements and closing targeted for late 2026 or early 2027

SanBio Co., Ltd. hereby announces that SanBio has entered into a business alliance with Ocumension Limited.